Ken Nakata

6PUBLICATIONS
13CO-AUTHORS
HaematologyPredictive and prognostic markersPharmaceutical delivery technologiesCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 01, 2026
Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".

|May 08, 2026
Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study.

|Feb 12, 2026
Effectiveness of denosumab, teriparatide and romosozumab for glucocorticoid-induced osteoporosis: a propensity score-matched cohort study.

Toshitaka Yukishima, Tomonori Kobayakawa, Yuji Hirano

|Mar 20, 2025
Author response to letter to the editor, (OSIN-D-25-00227) "From bisphosphonates to advanced therapies: a critical review of osteoporosis treatment strategies".

Toshitaka Yukishima, Kosuke Ebina, Yuki Etani

|Jan 17, 2025
Impact of switching from bisphosphonates to denosumab, teriparatide, or romosozumab in patients with postmenopausal osteoporosis: a case-control study.

Toshitaka Yukishima, Kosuke Ebina, Yuki Etani

|Aug 04, 2021
Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer.

Ken Nakata, Takamichi Komori, Kazuhiro Saso

Pageof 1

Frequent Collaborators

5 joint publications

Toshitaka Yukishima

5 joint publications

Kosuke Ebina

5 joint publications

Yuki Etani

5 joint publications

Takaaki Noguchi